Core Viewpoint - NetraMark Holdings Inc. has successfully closed the first tranche of a non-brokered private placement, raising gross proceeds of $3,110,000, which will be utilized for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The first tranche involved the issuance of 3,110,000 units at a price of $1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional common share at an exercise price of $1.35 for a period of two years from the closing date [2]. - The securities issued are subject to a hold period expiring on May 28, 2026, as per applicable securities laws [3]. Group 2: Future Tranche and Financial Commitments - The company has received commitments for the second and final tranche of the private placement, expected to close soon for additional gross proceeds of $390,000 [4]. - Following the first tranche, there are now 91,778,520 common shares of NetraMark issued and outstanding [3]. Group 3: Insider Participation - Certain insiders participated in the first tranche, subscribing for a total of 2,060,000 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the nature of the transaction and its market capitalization [5]. Group 4: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [8]. - The company's AI technology, NetraAI, is designed to improve clinical trial success rates by effectively segmenting patient data into explainable and unexplainable subsets, addressing issues of overfitting common in other AI methods [7].
NetraMark Closes First Tranche of Private Placement